Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

Overview

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

Full Title of Study: “Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Patients With Type 1 Diabetes Using Vibration-Controlled Transient Elastography and Noninvasive Scores”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: August 19, 2022

Detailed Description

This is a prospective cohort, single-center, single-arm study screening adult subjects with type 1 diabetes from the Joslin Diabetes Center outpatient clinic mainly through physician referrals for NAFLD and advanced fibrosis. Subjects will undergo a one-time screening which will last for about 30 minutes. The following procedures will be conducted during the study visit: 1. Blood draw for metabolic measurements (HbA1c, lipid panel, ALT, AST, serum albumin, complete blood count-CBC) 2. FibroScan Measurements (LSM and CAP) 3. Anthropometric measurements (weight, height, BMI calculation, waist, and hip circumference) 4. Systolic and diastolic blood pressure Blood Draw: Samples of blood taken during the trial for laboratory testing will include the following metabolic measurements: AST, ALT, Platelets, percentage A1C, and lipid parameters (TC, LDL, HDL, TG). Fibroscan: Vibration controlled transient elastography (VCTE) or FibroScan® (EchoSens, Paris, France) is a simple aid to diagnose adult patients with chronic liver diseases. FibroScan provides a fast and reliable alternative to hepatic needle biopsy. In this 5-7 minute test, the investigator induces a mild amplitude shear wave into liver tissue from a small mechanical vibrator at the end of the FibroScan probe. VCTE evaluates a representative volume of the liver that is 100-fold greater than needle biopsy and the liver stiffness measurement (LSM) is expressed in kilopascals (kPa) with values >9.8 kPa being consistent with the presence of advanced fibrosis/cirrhosis. Typically, 10 successful VCTE measurements with a median interquartile range/median ration of less than 30% are needed to have a reliable LSM. FIB-4 Index: This is a noninvasive surrogate biomarker of advanced fibrosis that is calculated using the following formula: FIB-4 = Age (years)×AST (U/L)/[PLT(109/L)×√ALT(U/L)] (Sterling, Lissen et al. 2006) FIB-4>2.67 is consistent with the presence of advanced fibrosis with 80% PPV. NAFLD Fibrosis Score (NFS): This is a noninvasive surrogate biomarker of advanced fibrosis that is calculated using the following formula: NFS= -1.675 + 0.037 – age (years) + 0.094 – BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio – 0.013 × platelet count (×109/l) – 0.66 × albumin (g/dl). NFS>0.676 is consistent with the presence of advanced fibrosis Anthropometric measurements: These include weight, height, BMI calculation, waist, and hip measurements. Measurements will be done using standardized anthropometric techniques. Follow up may be required for High-risk patients with advanced fibrosis. If patient consents, referring or treating physicians will be notified and provided with fibroscan results for possible referral to hepatologists for further evaluation and intervention.

Interventions

  • Device: Transient Elastography
    • Transient elastography is a noninvasive imaging modality used to assess NAFLD and advanced fibrosis

Arms, Groups and Cohorts

  • Study Cohort
    • 533 adult subjects with type 1 diabetes with no secondary causes of fatty liver

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of subjects with NAFLD
    • Time Frame: Baseline (one time point evaluation)
    • Controlled Attenuation Parameter (CAP) will be used to define the presence of NAFLD
  • Proportion of subjects with advanced fibrosis
    • Time Frame: Baseline (one time point evaluation)
    • Transient elastography will be used to define the presence of fibrosis

Secondary Measures

  • Proportion of subjects with advanced fibrosis per NAFLD fibrosis score-NFS
    • Time Frame: Baseline (one time point evaluation)
    • NFS will be calculated using the following formula: NFS= -1.675 + 0.037 – age (years) + 0.094 – BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio – 0.013 × platelet count (×109/l) – 0.66 × albumin (g/dl).
  • Proportion of subjects with advanced fibrosis per Fibrosis-4 (FIB-4) index
    • Time Frame: Baseline (one time point evaluation)
    • FIB-4 will be calculated using the following formula: FIB-4 = Age (years)×AST (U/L)/[PLT(109/L)×√ALT(U/L)]
  • HbA1c
    • Time Frame: Baseline (one time point evaluation)
    • Association with level of diabetes control as reflected in percentage HbA1c
  • Anthropometrics
    • Time Frame: Baseline (one time point evaluation)
    • Association with BMI and waist circumference
  • Lipid profile
    • Time Frame: Baseline (one time point evaluation)
    • Association with lipid parameters (LDL, HDL, TG)

Participating in This Clinical Trial

Inclusion Criteria

1. Subject is male or female 2. Subject age between 18-75 years old 3. Subject with an established diagnosis of T1D for at least three months prior to screening Exclusion Criteria:

1. Subject is pregnant or lactating 2. Subject has an active malignancy 4.Subject with secondary causes of fatty liver including history of any of the following:

  • Hepatitis B or C virus infection – Wilson's disease – Lipodystrophy – Abetalipoproteinemia – Current or previous use of any of the following medication: amiodarone, tamoxifen, methotrexate,corticosteroids (e.g. Prednisone), or Valproate – Male subject consuming >30 g of alcohol per day or female subject consuming >20 g of alcohol perday

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Joslin Diabetes Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Osama Hamdy, MD PhD, Principal Investigator, Joslin Diabetes Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.